How many drugs treat Supraventricular tachycardia?

Drug Landscape tracks 4 marketed treatments for Supraventricular tachycardia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/supraventricular-tachycardia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Supraventricular tachycardia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Supraventricular tachycardia (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Supraventricular tachycardia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Onoact	LANDIOLOL	Aop Hlth Us	landiolol	Beta-1 adrenergic receptor	2024-01-01
Brevibloc In Plastic Container	ESMOLOL	Pfizer	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1986-01-01
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Brevibloc	Brevibloc	AOP Orphan Pharmaceuticals AG		Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AOP Orphan Pharmaceuticals AG · 1 drug in Supraventricular tachycardia
Aop Hlth Us · 1 drug in Supraventricular tachycardia
Generic (originally ICI/AstraZeneca) · 1 drug in Supraventricular tachycardia
Pfizer · 1 drug in Supraventricular tachycardia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Supraventricular tachycardia:

Cite this brief

Drug Landscape (2026). Supraventricular tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/supraventricular-tachycardia. Accessed 2026-06-10.

Supraventricular tachycardia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing